castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
Company profile
Ticker
CSTL
Exchange
Website
CEO
Derek J. Maetzold
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AltheaDx, Inc. • Cernostics, Inc. • Myriad myPath, LLC • Castle Narnia Way Real Estate Holding 1, LLC ...
IRS number
770701744
CSTL stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
ARS
2024 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Entry into a Material Definitive Agreement
27 Mar 24
S-8
Registration of securities for employees
28 Feb 24
S-3
Shelf registration
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
28 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
Transcripts
CSTL
Earnings call transcript
2023 Q3
2 Nov 23
CSTL
Earnings call transcript
2023 Q2
2 Aug 23
CSTL
Earnings call transcript
2023 Q1
3 May 23
CSTL
Earnings call transcript
2022 Q4
28 Feb 23
CSTL
Earnings call transcript
2022 Q3
2 Nov 22
CSTL
Earnings call transcript
2022 Q2
12 Aug 22
CSTL
Earnings call transcript
2022 Q1
10 May 22
CSTL
Earnings call transcript
2021 Q4
1 Mar 22
CSTL
Earnings call transcript
2021 Q3
9 Nov 21
CSTL
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
4
DEREK J MAETZOLD
25 Apr 24
4
DEREK J MAETZOLD
16 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
4
DANIEL BRADBURY
10 Apr 24
4
DANIEL BRADBURY
8 Apr 24
4
DEREK J MAETZOLD
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Rodney Cotton
28 Mar 24
3
Rodney Cotton
28 Mar 24
4
DEREK J MAETZOLD
22 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.22 mm | 91.22 mm | 91.22 mm | 91.22 mm | 91.22 mm | 91.22 mm |
Cash burn (monthly) | 1.55 mm | 3.58 mm | 3.21 mm | 7.10 mm | (no burn) | 2.52 mm |
Cash used (since last report) | 10.69 mm | 24.68 mm | 22.16 mm | 48.93 mm | n/a | 17.36 mm |
Cash remaining | 80.53 mm | 66.54 mm | 69.07 mm | 42.29 mm | n/a | 73.86 mm |
Runway (months of cash) | 51.9 | 18.6 | 21.5 | 6.0 | n/a | 29.3 |
Institutional ownership, Q3 2023
92.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 138 |
Opened positions | 22 |
Closed positions | 16 |
Increased positions | 52 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 376.01 bn |
Total shares | 25.31 mm |
Total puts | 25.30 k |
Total calls | 60.00 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Wasatch Advisors | 2.78 mm | $46.97 bn |
Granahan Investment Management | 2.49 mm | $42.02 bn |
BLK Blackrock | 2.14 mm | $36.08 bn |
PFG Principal Financial Group Inc - Registered Shares | 1.48 mm | $25.03 bn |
Vanguard | 1.44 mm | $24.31 bn |
BLVGF Bellevue | 1.23 mm | $20.74 bn |
Sofinnova HealthQuest Partners | 983.58 k | $52.32 mm |
Deerfield Management | 946.62 k | $15.99 bn |
Bradbury Daniel | 743.42 k | $49.92 mm |
Kornitzer Capital Management | 648.22 k | $10.95 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.109 | 69 | 1.39 k | 9,683 |
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.109 | 69 | 1.39 k | 9,683 |
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.109 | 69 | 1.39 k | 9,683 |
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.109 | 68 | 1.37 k | 9,685 |
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.109 | 215 | 4.32 k | 75,015 |
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.109 | 215 | 4.32 k | 86,118 |
23 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | No | Yes | 20.109 | 421 | 8.47 k | 64,997 |
12 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.35 | 317 | 6.45 k | 9,752 |
12 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.35 | 317 | 6.45 k | 9,752 |
12 Apr 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.35 | 317 | 6.45 k | 9,752 |
News
Castle Biosciences Gives Long-Term Outcomes Data Shared At SSO 2024 Show That Patients With A Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free At 3-Years, Including Those Who Utilized The Test To Help Guide the Decision To Avoid An SLNB
22 Mar 24
Castle Biosciences New Study Showing The Drug-Drug Interactions And Lifestyle Factors Provided By ' IDgenetix Test Improve Medication Recommendations Over Drug-Gene Interactions Alone For Patients 65 And Older
15 Mar 24
Castle Biosciences To Present New Data Highlighting The Clinical Value Of Its Dermatologic Tests For Patients With Skin Cancer At The 2024 American Academy Of Dermatology Annual Meeting
8 Mar 24
Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $28
1 Mar 24
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
1 Mar 24
Press releases
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
11 Apr 24
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
10 Apr 24
Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
4 Apr 24
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Castle Biosciences Announces Updates to its Board of Directors
27 Mar 24